Author Title Type [ Year(Desc)]
Filters: Author is Yakoub-Agha, Ibrahim  [Clear All Filters]
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Díez-Martín JL, Corradini P, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.
Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, et al. Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT. Am J Hematol. 2018.
Cornillon J, Detrait M, Karam M, Le Bars L, Meziane Y, Pereira M, Richard-Leveille S, Marion S, Leroux S, Coiteux V, et al. [Harmonization of data coding in post-transplant follow-up - "GVHD, complications and additional treatments": Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2018.
Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, et al. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JHenri, et al. Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu. Am J Hematol. 2018.
Belkacemi Y, Labopin M, Giebel S, Gorin NClaude, Loganadane G, Miszczyk L, Michallet M, Socié G, Schaap NPm, Cornelissen JJ, et al. Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. Int J Radiat Oncol Biol Phys. 2018.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, et al. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell. Bone Marrow Transplant. 2019.
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gulbas Z, Wallet HL, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R, Milpied N, Angelucci E, Yakoub-Agha I, Michallet M, et al. Myeloablative unrelated cord blood transplantation in adolescents and young adults with acute leukemia. Biol Blood Marrow Transplant. 2019.
Gagelmann N, Eikema D-J, Koster L, Caillot D, Pioltelli P, Lleonart JBargay, Reményi P, Blaise D, Schaap N, Trneny M, et al. Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2019.